From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity

Brain

Volumn 122, Issue 6, 1999, Pages 1133-1146

  Krack, Paul ^a,b   Pollak, Pierre ^a   Limousin, Patricia ^a,c   Benazzouz, Abdelhamid ^a   Deuschl, Günther ^b   Benabid, Alim Louis ^a  

^a UNIV GRENOBLE ALPES   (France)

^b UNIVERSITY OF KIEL   (Germany)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Deep brain stimulation; Dystonia; Levodopa induced dyskinaesias; Parkinson's disease; Subthalamic nucleus

Indexed keywords

LEVODOPA;

ADULT; ARTICLE; CHOREA; CLINICAL ARTICLE; DYSKINESIA; DYSTONIA; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; SUBTHALAMIC NUCLEUS;

EID: 0032692741     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/122.6.1133     Document Type: Article

References (111)

1. Agid Y, Bonnet A, Signoret J, Lhermitte F. Clinical, pharmacological, and biochemical approach of 'onset- and end-of-dose' dyskinaesias. Adv Neurol 1979; 24: 401-10.
2. Agid Y, Bonnet A, Ruberg M, Javoy-Agid F. Pathophysiology of L-dopa-induced abnormal involuntary movements. In: Casey DE, Chase TN, Christensen AV, Gerlach J, editors. Dyskinesia. Berlin: Springer; 1985. p. 145-59.
3. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989; 12: 366-75.
4. Arnulf I, Bejjani B, Garma L, Bonnet AM, Damier P, Derenne JP, et al. Effect of deep brain stimulation on sleep in Parkinson's disease [abstract]. Neurology 1998; 50 Suppl 4: A262.
5. Barbeau A. L-Dopa therapy in Parkinson's disease: a critical review of nine years experience. Can Med Assoc J 1969; 101: 791-800.
6. Barbeau A. Long-term side-effects of levodopa. Lancet 1971; 1: 395.
7. Barbeau A. Diphasic dyskinaesias during levodopa therapy [letter]. Lancet 1975; 1: 756.
8. Barbeau A. Six years of high-level levodopa therapy in severely akinetic parkinsonian patients. Arch Neurol 1976; 33: 333-8.
9. Baron MS, Vitek JL, Bakay RA, Green J, Kaneoke Y, Hashimoto T, et al. Treatment of advanced Parkinson's disease by posterior GPi pallidototny: 1-year results of a pilot study [see comments]. Ann Neurol 1996; 40: 355-366. Comment in: Ann Neurol 1996; 40: 341-3, Comment in: Ann Neurol 1997; 41: 129-30.
10. Baron MS, Vitek JL, Bakay RA, Green J, Kaneoke Y, Hashimoto T, et al. Treatment of advanced Parkinson's disease by posterior GPi pallidototny: 1-year results of a pilot study [see comments]. Ann Neurol 1996; 40: 355-366. Comment in: Ann Neurol 1996; 40: 341-3, Comment in: Ann Neurol 1997; 41: 129-30.
11. Baron MS, Vitek JL, Bakay RA, Green J, Kaneoke Y, Hashimoto T, et al. Treatment of advanced Parkinson's disease by posterior GPi pallidototny: 1-year results of a pilot study [see comments]. Ann Neurol 1996; 40: 355-366. Comment in: Ann Neurol 1996; 40: 341-3, Comment in: Ann Neurol 1997; 41: 129-30.
12. Bédard PJ, Mancilla BG, Blanchette P, Gagnon C, Di Paolo T. Levodopa-induced dyskinesia: facts and fancy. What does the MPTP monkey model tell us? [Review]. Can J Neurol Sci 1992;19(1 Suppl): 134-7.
13. Benabid AL, Pollak P, Gervason C, Hoffmann D, Gao DM, Hommel M, et al. Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 1991; 337: 403-6.
14. Benabid AL, Pollak P, Gao D, Hoffmann D, Limousin P, Gay E, et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders [see comments]. J Neurosurg 1996; 84: 203-214. Comment in: J Neurosurg 1997; 86: 737.
15. Benabid AL, Pollak P, Gao D, Hoffmann D, Limousin P, Gay E, et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders [see comments]. J Neurosurg 1996; 84: 203-214. Comment in: J Neurosurg 1997; 86: 737.
16. Benazzouz A, Gross C, Féger J, Boraud T, Bioulac B. Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur J Neurosci 1993; 5: 382-9.
17. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990; 249: 1436-8.
18. Bergman H, Wichmann T, Karmon B, DeLong M. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 1994; 72: 507-20.
19. Bergmann KJ, Mendoza MR, Yahr MD. Parkinson's disease and long-term levodopa therapy. Adv Neurol 1987; 45; 463-7.
20. Blanchet, PJ, Gomez-Mancilla B, Bedard PJ. DOPA-induced 'peak-dose' dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys. [Review]. J Neural Transm Suppl 1995; 45: 103-12.
21. Blanchet PJ, Allard P, Gregoire L, Tardif F, Bedard PJ. Risk factors for peak-dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci 1996; 23: 189-93.
22. Blin J, Bonnet AM, Agid Y. Does levodopa aggravate Parkinson's disease? Neurology 1988; 38: 1410-6.
23. Boyce S, Rupniak NMJ, Steventon MJ, Iversen SD. Nigrostriatal damage is required for induction of dyskinaesias by L-DOPA in squirrel monkeys. Clin Neuropharmacol 1990; 13: 448-58.
24. Caparros Lefebvre D, Blond S, Vermersch R, Pecheux N, Guieu JD, Petit H. Chronic thalamic stimulation improves tremor and levodopa induced dyskinaesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1993; 56: 268-73.
25. Cedarbaum JM, Gandy SE, McDowell FH. 'Early' initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinaesias, or dementia in Parkinson's disease. Neurology 1991; 41: 622-9.
26. Charcot JM. Cinquième leçon: de la paralysie agitante. In: Bourneville M, editor. Oeuvres complètes de J.M. Charcot. Leçons sur les maladies du système nerveux. Paris: Delahaye; 1892. p. 155-88.
27. Chase TN, Engber TM, Mouradian MM. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. [Review]. Adv Neurol 1996; 69: 497-501.
28. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinaesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64: 573-6.
29. Cooper IS. Surgical alleviation of parkinsonism: effects of occlusion of the anterior choroidal artery. J Am Geriatrics Soc 1954; 2: 691-718.
30. Cooper IS. Neurosurgical treatment of the dyskinaesias. Clin Neurosurg 1977; 24: 367-90.
31. Cooper IS, Bravo GJ, Riklan M, Davidson NW, Gorek EA. Chemopallidectomy and chemothalamectomy for parkinsonism. Geriatrics 1958; 13: 127-47.
32. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. New Engl J Med 1967; 276: 374-9.
33. Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism: chronic treatment with L-dopa. N Engl J Med 1969; 280: 337-15.
34. de Saint Victor JF, Pollak P, Gervason CL, Perret J. Levodopa-induced diphasic dyskinaesias improved by subcutaneous apomorphine [letter]. Mov Disord 1992; 7: 283-4.
35. Denny-Brown D. The basal ganglia. Glasgow: Oxford University Press; 1962.
36. Dogali M, Fazzini E, Kolodny E, Eidelberg D, Sterio D, Devinsky O, et al. Stereotactic ventral pallidotomy for Parkinson's disease. Neurology 1995; 45: 753-61.
37. Duvoisin RC, Yahr MD, Lieberman J, Antunes J, Rhee S. The striatal foot. Trans Am Neurol Assoc 1972; 97: 267.
38. Fahn S. Fluctuations of disability in Parkinson's disease: pathophysiology. In: Marsden CD, Fahn S, editors. Movement disorders. London: Butterworth; 1982. p. 123-45.
39. Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, editors. Recent developments in Parkinson's disease. Florham Park (NJ): MacMillan Health Care Information; 1987. p. 153-63.
40. Garcin R. Syndrome cérébello-thalamique par lésion localisée du thalamus. Avec une digression sur le 'signe de la main creuse' et son intérêt séméiologique. Rev Neurol (Paris) 1955; 93: 143-9.
41. Gibb WR, Lees AJ. A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology 1988; 38: 1402-6.
42. Gill SS, Heywood P. Bilateral dorsolateral subthalamotomy for advanced Parkinson's disease [letter]. Lancet 1997; 350: 1224.
43. Gioino GG, Dierssen G, Cooper IS. The effect of subcortical lesions on production and alleviation of hemiballic or hemichoreic movements. J Neurol Sci 1966; 3: 10-36.
44. Goetz CG, Stebbins GT, Shale HM, Lang AE, Chernik DA, Chmura TA, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment [see comments]. Mov Disord 1994; 9: 390-94. Comment in: Mov Disord 1995; 10: 527-8.
45. Goetz CG, Stebbins GT, Shale HM, Lang AE, Chernik DA, Chmura TA, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment [see comments]. Mov Disord 1994; 9: 390-94. Comment in: Mov Disord 1995; 10: 527-8.
46. Goulet M, Morissette M, Calon F, Blanchet PJ, Falardeau P, Bedard PJ, et al. Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis. Neuroscience 1997; 79: 497-507.
47. Grondin R, Goulet M, Di Paolo T, Bedard PJ. Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinaesias in parkinsonian drug-naive primates. Brain Res 1996; 735: 298-306.
48. Guiot G, Brion S. Traitement neurochirurgical des syndromes choréoathétosique et parkinsonien. Sem Hop Paris 1952; 28: 2095-9.
49. Horstink MWI, Zijlmans JC, Pasman JW, Berger HJ, van't Hof MA. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. J Neurol Neursourg Psychiatry 1990; 53: 224-6.
50. Hutchinson WD, Levy R, Dostrovsky JO, Lozano AM, Lang AE. Effects of apomorphine on globus pallidus neurons in parkinsonian patients. Ann Neurol 1997; 42: 767-75.
51. Ilson J, Fahn S, Cote L. Painful dystonic spasms in Parkinson's disease. Adv Neurol 1984; 40: 395-8.
52. Krack P, Limousin P, Benabid AL, Pollak P. Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinaesias in Parkinson's disease [letter]. Lancet 1997a; 350: 1676.
53. Krack P, Pollak P, Limousin P, Benazzouz A, Benabid AL. Stimulation of subthalamic nucleus alleviates tremor in Parkinson's disease [letter]. Lancet 1997b; 350: 1675.
54. Krack P, Pollak P, Limousin P, Hoffmann D, Benazzouz A, Le Bas JF, et al. Opposite motor effects of pallidal stimulation in Parkinson's disease. Ann Neurol 1998a; 43: 180-92.
55. Krack P, Pollak P, Limousin P, Hoffmann D, Xie J, Benazzouz A, et al. Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. Brain 1998b; 121: 451-7.
56. Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease [see comments]. J Neurosurg 1992; 76: 53-61. Comment in: J Neurosurg 1992; 77: 487-8.
57. Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease [see comments]. J Neurosurg 1992; 76: 53-61. Comment in: J Neurosurg 1992; 77: 487-8.
58. Langston JW, Widner H, Goetz CG, Brooks D, Fahn S, Freeman T, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992; 7: 2-13.
59. Lees AJ, Shaw KM, Stern GM. 'Off period' dystonia and 'on period' choreoathetosis in levodopa-treated patients with Parkinson's disease [letter]. Lancet 1977; 2: 1034.
60. Lhermitte F, Agid Y, Signoret JL, Studler JM. Les dyskinésies de 'début et fin de dose' provoquées par la L-DOPA. Rev Neurol (Paris) 1977; 133: 297-308.
61. Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas JF, Broussolle E, et al. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995; 345: 91-5.
62. Limousin P, Pollak P, Hoffmann D, Benazzouz A, Perret JE, Benabid AL. Abnormal involuntary movements induced by subthalamic nucleus stimulation on Parkinsonian patients. Mov Disord 1996; 11: 231-5.
63. Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998; 339: 1105-11.
64. Lozano AM, Lang AE, Galvez-Jimenez N, Miyasaki J, Duff J, Hutchinson WD, et al. Effect of GPi pallidotomy on motor function in Parkinson's disease [see comments] [published erratum appears in Lancet 1996; 348: 1108]. Lancet 1995; 346: 1383-7. Comment in: Lancet 1996; 347: 1490.
65. Lozano AM, Lang AE, Galvez-Jimenez N, Miyasaki J, Duff J, Hutchinson WD, et al. Effect of GPi pallidotomy on motor function in Parkinson's disease [see comments] [published erratum appears in Lancet 1996; 348: 1108]. Lancet 1995; 346: 1383-7. Comment in: Lancet 1996; 347: 1490.
66. Lozano AM, Kumar R, Gross RE, Giladi N, Hutchinson WD, Dostrovsky JO, et al. Globus pallidus internus pallidotomy for generalized dystonia [see comments]. Mov Disord 1997; 12: 865-870. Comment in: Mov Disord 1997; 12: 841.
67. Lozano AM, Kumar R, Gross RE, Giladi N, Hutchinson WD, Dostrovsky JO, et al. Globus pallidus internus pallidotomy for generalized dystonia [see comments]. Mov Disord 1997; 12: 865-870. Comment in: Mov Disord 1997; 12: 841.
68. Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinaesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992; 7: 117-24.
69. Marconi R, Lefebvre-Caparros D, Bonnet A, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinaesias in Parkinson's disease. Phenomenology and pathophysiology. Mov Disord 1994; 9: 2-12.
70. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability of Parkinson's disease - clinical aspects. In: Marsden CD, Fahn S, editors. Movement Disorders. London; Butterworth: 1982. p. 96-122.
71. Martin JP. Hemichorea resulting from a local lesion of the brain (the syndrome of the body of Luys). Brain 1927; 50: 637-51.
72. McHale DM, Sage JI, Sonsalla PK, Vitigliano D. Complex dystonia of Parkinson's disease: clinical features and relation to plasma levodopa profile. Clin Neuropharmacol 1990; 13: 164-70.
73. Melamed E. Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease. Arch Neurol 1979; 36: 308-10.
74. Merello JM and Lees AJ. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease. J Neurol Neurosurg Psychiatry 1992;55:1024-6.
75. Mones RJ, Elizan TS, Siegel GJ. Analysis of L-dopa induced dyskinaesias in 51 patients with parkinsonism. J Neurol Neurosurg Psychiatry 1971; 34: 668-73.
76. Mouradian MM, Heuser IF, Baronti F, Fabbrini G, Juncos JL, Chase TN. Pathogenesis of dyskinaesias in Parkinson's disease. Ann Neurol 1989; 25: 523-6.
77. Mouradian MM, Heuser IJ, Baronti F, Chase TN. Modification of central dopaminergic mechanisms with continuous levodopa therapy for advanced Parkinson' s disease. Ann Neurol 1990; 27: 18-23.
78. Muenter MD, Sharpless NS, Tyce GM, Darley FL. Patterns of dystonia ('I-D-I' and 'D-I-D') in response to L-dopa therapy for Parkinson's disease. Mayo Clin Proc 1977; 52: 163-74.
79. Mundinger F. Die Subthalamotomie zur Behandlung extrapyramidaler Bewegungsstörungen. Dtsch Med Wochenschr 1965; 90: 2002-7.
80. Narabayashi H, Yakochi F, Nakajima Y. Levodopa-induceddyskinesia and thalamotomy. J Neurol Neurosurg Psychiatry 1984; 47: 831-9.
81. Nausieda PA, Weiner WJ, Klawans HL. Dystonic foot response of parkinsonism. Arch Neurol 1980; 37: 132-6.
82. Nutt JG and Holford NH. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. [Review]. Ann Neurol 1996; 39: 561-73.
83. Nygaard TG, Marsden CD, Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology 1991; 41: 174-81.
84. Obeso JA, Alvarez LM, Macias RJ, Guridi J, Teijeiro J, Juncos J, et al. Lesion of the subthalamic nucleus in Parkinson's disease. Neurology 1997; 48 (3Suppl 2): A138.
85. Obeso JA, Grandas F, Herrero MT, Horowski R. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. [Review]. Eur J Neurosci 1994; 6: 889-97.
86. Ondo WG, Desaloms JM, Jankovic J, Grossman RG. Pallidotomy for generalized dystonia. Mov Disord 1998; 13: 693-8.
87. Page RD, Sambrook MA, Crossman AR. Thalamotomy for the alleviation of levodopa-induced dyskinesia: experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treated parkinsonian monkey. Neuroscience 1993; 55: 147-65.
88. Parkes JD, Bedard P, Marsden CD. Chorea and torsion in parkinsonism [letter]. Lancet 1976; 2: 155.
89. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa [see comments]. Ann Neurol 1996; 39: 37-45. Comment in: Ann Neurol 1996; 40: 946-8.
90. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa [see comments]. Ann Neurol 1996; 39: 37-45. Comment in: Ann Neurol 1996; 40: 946-8.
91. Poewe WH, Lees AJ. The pharmacology of foot dystonia in parkinsonism. [Review]. Clin Neuropharmacol 1987; 10: 47-56.
92. Poewe W, Lees AJ, Steiger D, Stern GM. Foot dystonia in Parkinson's disease: clinical phenomenology and neuro-pharmacology. Adv Neurol 1987; 45: 357-60.
93. Poewe WH, Lees AJ, Stem GM. Dystonia in Parkinson's disease: clinical and pharmacological features. Ann Neurol 1988; 23: 73-8.
94. Quinn NP, Koller WC, Lang AE, Marsden CD. Painful Parkinson's disease. Lancet 1986; 1: 1366-9.
95. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987; 2: 73-91.
96. Sage JI, Mark MH. The rationale for continuous dopaminergic stimulation in patients with Parkinson's disease. [Review]. Neurology 1992; 42 (1 Suppl 1): 23-8.
97. Schneider JS. Levodopa-induced dyskinaesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav 1989; 34: 193-6.
98. Schuh LA, Bennett JP Jr. Suppression of dyskinaesias in advanced Parkinson's disease. Continuous intravenous levodopa shifts dose response for production of dyskinaesias but not for relief of parkinsonism in patient with advanced Parkinson's disease [see comments]. Neurology 1993; 43: 1545-1550. Comment in: Neurology 1994; 44: 1187.
99. Schuh LA, Bennett JP Jr. Suppression of dyskinaesias in advanced Parkinson's disease. Continuous intravenous levodopa shifts dose response for production of dyskinaesias but not for relief of parkinsonism in patient with advanced Parkinson's disease [see comments]. Neurology 1993; 43: 1545-1550. Comment in: Neurology 1994; 44: 1187.
100. Shannon KM. Hemiballismus. [Review]. Clin Neuropharmacol 1990; 13: 413-25.
101. Siegfried J, Lippitz B. Bilateral chronic electrostimulation of ventroposterolateral pallidum: a new therapeutic approach for alleviating all parkinsonian symptoms. Neurosurgery 1994; 35: 1126-30.
102. Stewart P. Paralysis agitans with an account of a new symptom. Lancet, 1898; 2: 1258-60.
103. Suarez JI, Verhagen Metman L, Reich SG, Dougherty PM, Hallett M, Lenz FA. Pallidotomy for hemiballismus: efficacy and characteristics of neuronal activity. Ann Neurol 1997; 42: 807-11.
104. Syed N, Murphy J, Zimmerman T Jr, Mark MH, Sage JI. Ten years' experience with enterai levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord 1998; 13: 336-8.
105. Talairach J, Paillas J, David M. Dyskinésie de type hémiballique traitée par cortectomie frontale limitée, puis par coagulation de l'anse lenticulaire et de la portion interne du globus pallidus. Amélioration importante depuis un an. Rev Neurol (Paris) 1950; 83: 440-51.
106. Tolosa ES, Martin WE, Cohen HP. Dyskinesias during levodopa therapy [letter]. Lancet 1975; I: 1381-2.
107. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinaesias and motor fluctuations in Parkinson's disease [see comments]. Neurology 1998; 50: 1323-6. Comment in: Neurology 1998; 50: 1211-2.
108. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinaesias and motor fluctuations in Parkinson's disease [see comments]. Neurology 1998; 50: 1323-6. Comment in: Neurology 1998; 50: 1211-2.
109. Wang Y, Turnbull I, Calne S, Stoessl A, Calne DB. Pallidotomy for tardive dyskinesia [letter]. Lancet 1997; 349: 777-8.
110. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol 1969; 21: 343-54.
111. Zimmerman TR Jr, Sage JI, Lang AE, Mark MH. Severe evening dyskinaesias in advanced Parkinson' s disease: clinical description, relation to plasma levodopa, and treatment. Mov Disord 1994; 9: 173-7.